These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

182 related articles for article (PubMed ID: 30830863)

  • 1. Secreted cellular prion protein binds doxorubicin and correlates with anthracycline resistance in breast cancer.
    Wiegmans AP; Saunus JM; Ham S; Lobb R; Kutasovic JR; Dalley AJ; Miranda M; Atkinson C; Foliaki ST; Ferguson K; Niland C; Johnstone CN; Lewis V; Collins SJ; Lakhani SR; Al-Ejeh F; Möller A
    JCI Insight; 2019 Feb; 5(6):. PubMed ID: 30830863
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Low expression levels of ATM may substitute for CHEK2 /TP53 mutations predicting resistance towards anthracycline and mitomycin chemotherapy in breast cancer.
    Knappskog S; Chrisanthar R; Løkkevik E; Anker G; Østenstad B; Lundgren S; Risberg T; Mjaaland I; Leirvaag B; Miletic H; Lønning PE
    Breast Cancer Res; 2012 Mar; 14(2):R47. PubMed ID: 22420423
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Activation of Akt characterizes estrogen receptor positive human breast cancers which respond to anthracyclines.
    Yndestad S; Austreid E; Svanberg IR; Knappskog S; Lønning PE; Eikesdal HP
    Oncotarget; 2017 Jun; 8(25):41227-41241. PubMed ID: 28476032
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Increased cellular accumulation and distribution of amrubicin contribute to its activity in anthracycline-resistant cancer cells.
    Mamidipudi V; Shi T; Brady H; Surapaneni S; Chopra R; Aukerman SL; Heise C; Sung V
    Cancer Chemother Pharmacol; 2012 Apr; 69(4):965-76. PubMed ID: 22120960
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prognostic implication of HSPA (HSP70) in breast cancer patients treated with neoadjuvant anthracycline-based chemotherapy.
    Nadin SB; Sottile ML; Montt-Guevara MM; Gauna GV; Daguerre P; Leuzzi M; Gago FE; Ibarra J; Cuello-Carrión FD; Ciocca DR; Vargas-Roig LM
    Cell Stress Chaperones; 2014 Jul; 19(4):493-505. PubMed ID: 24307543
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Epirubicin: is it like doxorubicin in breast cancer? A clinical review.
    Khasraw M; Bell R; Dang C
    Breast; 2012 Apr; 21(2):142-9. PubMed ID: 22260846
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Multifactorial approach to predicting resistance to anthracyclines.
    Desmedt C; Di Leo A; de Azambuja E; Larsimont D; Haibe-Kains B; Selleslags J; Delaloge S; Duhem C; Kains JP; Carly B; Maerevoet M; Vindevoghel A; Rouas G; Lallemand F; Durbecq V; Cardoso F; Salgado R; Rovere R; Bontempi G; Michiels S; Buyse M; Nogaret JM; Qi Y; Symmans F; Pusztai L; D'Hondt V; Piccart-Gebhart M; Sotiriou C
    J Clin Oncol; 2011 Apr; 29(12):1578-86. PubMed ID: 21422418
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Induction of 1C aldoketoreductases and other drug dose-dependent genes upon acquisition of anthracycline resistance.
    Veitch ZW; Guo B; Hembruff SL; Bewick AJ; Heibein AD; Eng J; Cull S; Maclean DA; Parissenti AM
    Pharmacogenet Genomics; 2009 Jun; 19(6):477-88. PubMed ID: 19440163
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Silencing of prion protein sensitizes breast adriamycin-resistant carcinoma cells to TRAIL-mediated cell death.
    Meslin F; Hamaï A; Gao P; Jalil A; Cahuzac N; Chouaib S; Mehrpour M
    Cancer Res; 2007 Nov; 67(22):10910-9. PubMed ID: 18006836
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Twist confers chemoresistance to anthracyclines in bladder cancer through upregulating P-glycoprotein.
    Chen Y; Li L; Zeng J; Wu K; Zhou J; Guo P; Zhang D; Xue Y; Liang L; Wang X; Chang LS; He D
    Chemotherapy; 2012; 58(4):264-72. PubMed ID: 22986993
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Circular RNA La-related RNA-binding protein 4 correlates with reduced tumor stage, as well as better prognosis, and promotes chemosensitivity to doxorubicin in breast cancer.
    Zhang X; Su X; Guo Z; Jiang X; Li X
    J Clin Lab Anal; 2020 Jul; 34(7):e23272. PubMed ID: 32187743
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Downregulation of histone H2A and H2B pathways is associated with anthracycline sensitivity in breast cancer.
    Braunstein M; Liao L; Lyttle N; Lobo N; Taylor KJ; Krzyzanowski PM; Kalatskaya I; Yao CQ; Stein LD; Boutros PC; Twelves CJ; Marcellus R; Bartlett JM; Spears M
    Breast Cancer Res; 2016 Feb; 18(1):16. PubMed ID: 26852132
    [TBL] [Abstract][Full Text] [Related]  

  • 13. PRMT5 determines the sensitivity to chemotherapeutics by governing stemness in breast cancer.
    Wang Z; Kong J; Wu Y; Zhang J; Wang T; Li N; Fan J; Wang H; Zhang J; Ling R
    Breast Cancer Res Treat; 2018 Apr; 168(2):531-542. PubMed ID: 29185119
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Predictive value of apoptosis, proliferation, HER-2, and topoisomerase IIalpha for anthracycline chemotherapy in locally advanced breast cancer.
    Arpino G; Ciocca DR; Weiss H; Allred DC; Daguerre P; Vargas-Roig L; Leuzzi M; Gago F; Elledge R; Mohsin SK
    Breast Cancer Res Treat; 2005 Jul; 92(1):69-75. PubMed ID: 15980993
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Alterations in estrogen signalling pathways upon acquisition of anthracycline resistance in breast tumor cells.
    Chewchuk S; Guo B; Parissenti AM
    PLoS One; 2017; 12(2):e0172244. PubMed ID: 28196134
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Resistance to different anthracycline chemotherapeutics elicits distinct and actionable primary metabolic dependencies in breast cancer.
    McGuirk S; Audet-Delage Y; Annis MG; Xue Y; Vernier M; Zhao K; St-Louis C; Minarrieta L; Patten DA; Morin G; Greenwood CM; Giguère V; Huang S; Siegel PM; St-Pierre J
    Elife; 2021 Jun; 10():. PubMed ID: 34181531
    [TBL] [Abstract][Full Text] [Related]  

  • 17. MAPK overexpression is associated with anthracycline resistance and increased risk for recurrence in patients with triple-negative breast cancer.
    Eralp Y; Derin D; Ozluk Y; Yavuz E; Guney N; Saip P; Muslumanoglu M; Igci A; Kücücük S; Dincer M; Aydiner A; Topuz E
    Ann Oncol; 2008 Apr; 19(4):669-74. PubMed ID: 18006896
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Epirubicin versus doxorubicin: which is the anthracycline of choice for the treatment of breast cancer?
    Kaklamani VG; Gradishar WJ
    Clin Breast Cancer; 2003 Apr; 4 Suppl 1():S26-33. PubMed ID: 12756076
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy and toxicity of pegylated liposomal doxorubicin-based chemotherapy in early-stage breast cancer: a multicenter retrospective case-control study.
    Yang FO; Hsu NC; Moi SH; Lu YC; Hsieh CM; Chang KJ; Chen DR; Tu CW; Wang HC; Hou MF
    Asia Pac J Clin Oncol; 2018 Jun; 14(3):198-203. PubMed ID: 29045014
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Anthracyclines in the treatment of gynecologic malignancies.
    Maluf FC; Spriggs D
    Gynecol Oncol; 2002 Apr; 85(1):18-31. PubMed ID: 11925115
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.